跳至主要内容
临床试验/ACTRN12612000662864
ACTRN12612000662864已完成2 期

Randomised, controlled phase II trial of simvastatin as prophylaxis against radiation–induced skin toxicity in breast cancer patients

Waikato District Health Board0 个研究点目标入组 130 人开始时间: 2012年6月20日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
130

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
Female

入选标准

  • Patients with resected invasive cancer or carcinoma in-situ of the breast treated with either breast-conserving surgery or mastectomy who are planned to receive adjuvant radiation therapy.
  • Radiation fields may include the breast, chest wall, supraclavicular and/or axillary regions. Acceptable dose fractionation schedules include 50Gy in 25 fractions, 45Gy in 20 fractions, 42.5Gy in 16 fractions or 40Gy in 15 fractions, with or without a boost.
  • Patients may be taking adjuvant hormonal therapy and/or trastuzumab for breast cancer
  • Patients may have received prior adjuvant chemotherapy
  • Patients have given written informed consent

排除标准

  • Patients receiving other hypofractionated radiation schedules
  • Patients requiring the use of skin bolus with their radiotherapy
  • Patients with pre-existing ulceration, infection or skin rashes within the radiation treatment field
  • Known contra-indication to statins including hypersensitivity, active liver disease or unexplained persistent elevation of transaminases, concomitant administration of potent CYP3A4 inhibitors
  • Concurrent chemotherapy
  • Patients currently on statins or taken within the last 6 weeks
  • Current pregnancy or breast-feeding

研究者

相似试验